CYCLOBENZAPRINE 10 MG
CYCLOBENZAPRINE HYDROCHLORIDE : 10 MG · DIN 02171848 · APOTEX INC
Health Canada status: APPROVED
What is CYCLOBENZAPRINE?
CYCLOBENZAPRINE 10 MG contains CYCLOBENZAPRINE HYDROCHLORIDE : 10 MG. It is listed in the Health Canada Drug Product Database under DIN 02171848, held by APOTEX INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as approved, status dated 16-Dec-2020. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02171848 |
|---|---|
| Brand name | CYCLOBENZAPRINE |
| Generic / active ingredient | CYCLOBENZAPRINE HYDROCHLORIDE : 10 MG |
| Manufacturer | APOTEX INC |
| Strength | 10 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | M03BX08 CYCLOBENZAPRINE |
| AHFS class | 12:20.04 |
| Biosimilar | No |
| Health Canada status | APPROVED |
| Status date | 16-Dec-2020 |
How is this product identified?
Purchase orders, customs paperwork and tender documents each ask for a different identifier, and a DIN written without its leading zeros is the single most common reason an order line fails to match. Every form Nexara accepts for this product is listed here.
| DIN (8-digit, as used in Nexara ordering) | 02171848 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2171848 |
| Brand name | CYCLOBENZAPRINE |
| Active ingredient / INN | CYCLOBENZAPRINE HYDROCHLORIDE : 10 MG |
| ATC code | M03BX08 |
| ATC anatomical main group | M — Musculo-skeletal system |
| ATC therapeutic subgroup | M03 |
| AHFS class | 12:20.04 |
| Health Canada schedule | Prescription |
| Biosimilar biologic | No |
| Market authorization holder | APOTEX INC |
Which pack is which?
| Strength on the label | 10 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced. Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Is CYCLOBENZAPRINE in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Resolved — reported by SANIS HEALTH INC, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code M03BX08 CYCLOBENZAPRINE. 10 of 23 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| AG-CYCLOBENZAPRINE | 10 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02485419 |
| APO-CYCLOBENZAPRINE | 10 MG | TABLET | APOTEX INC | MARKETED | DIN 02177145 |
| AURO-CYCLOBENZAPRINE | 10 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02348853 |
| CYCLOBENZAPRINE | 10 MG | TABLET | SIVEM PHARMACEUTICALS ULC | MARKETED | DIN 02424584 |
| CYCLOBENZAPRINE | 10 MG | TABLET | SANIS HEALTH INC | MARKETED | DIN 02287064 |
| JAMP-CYCLOBENZAPRINE | 10 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02357127 |
| PMS-CYCLOBENZAPRINE - TAB 10MG | 10 MG | TABLET | PHARMASCIENCE INC | MARKETED | DIN 02212048 |
| PRO-CYCLOBENZAPRINE | 10 MG | TABLET | PRO DOC LIMITEE | MARKETED | DIN 02220644 |
| RIVA-CYCLOBENZAPRINE | 10 MG | TABLET | LABORATOIRE RIVA INC. | MARKETED | DIN 02242079 |
| TEVA-CYCLOBENZAPRINE | 10 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 02080052 |
Who else supplies CYCLOBENZAPRINE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. CYCLOBENZAPRINE appears in 17 registered pack listings across 4 markets, published on 3 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How much does CYCLOBENZAPRINE cost around the world?
CYCLOBENZAPRINE is listed on 2 national price registers Nexara tracks, across 83 pack listings published on 2 different price bases. What each country publishes is set out below.
| Market | What that country publishes | Brands listed | Pack listings | As of |
|---|---|---|---|---|
| United States | acquisition | 3 | 82 | 03 Sep 2026 |
| Iceland | max wholesale | 1 | 1 | 02 Sep 2026 |
Why there are no figures here. These bases are not comparable. A Brazilian ex-factory ceiling, a Belgian pharmacy public price and a Japanese reimbursement rate answer three different questions, and none of them is what a product lands in Canada for. Putting them side by side would mislead in both directions, so Nexara publishes where a molecule is listed and on what basis, and quotes the delivered Canadian price per order.
How can I get it?
This product is approved by Health Canada but not yet marketed in Canada, so there is no Canadian supply to draw on today. Nexara can tell you whether it has been launched, and can look at supply from other markets where a Canadian pack is not required or where importation is permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.